Clinical Trial Update: Ampicillin-sulbactam Resistant E.Coli at UPMC

View source ↗

Summary

A clinical trial evaluating ampicillin-sulbactam in Escherichia coli infections at UPMC has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Escherichia Coli Infection

Drugs mentioned

• Ampicillin-sulbactam (Ampicillin-sulbactam)

Snippet

Sponsor: University of Pittsburgh | Conditions: Positive E Coli Infections | Status: WITHDRAWN